Litigation Details for Neos Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Neos Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Docket		Date Filed	2017-12-13
Court	District Court, D. Delaware	Date Terminated	2019-01-02
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	NEOS THERAPEUTICS, INC.
Patents	8,840,924; 9,072,680; 9,089,496
Attorneys	Eric J. Shinabarger
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Neos Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-13				External link to document
2017-12-12	1		.S. patents by Teva: U.S. Patent Nos. 8,840,924 (“the ‘924 patent”); 9,072,680 (“the ‘680 patent”); and…. 13. The ‘924 patent, the ‘680 patent, and the ‘496 patent are all listed for COTEMPLA… the expiration of the ‘924 patent, the ‘680 patent, and the ‘496 patent. 15. Pursuant to… that the claims of the ‘924 patent, the ‘680 patent, and the ‘496 patent are invalid and/or will not…allegations with respect to the ‘924 patent, the ‘680 patent, and the ‘496 patent on or about October 31, 2017	External link to document
2017-12-12	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,840,924 B2; 9,072,680 B2; 9,089,496…2017 2 January 2019 1:17-cv-01793 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-12-12	41		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,840,924 B2 ;9,072,680 B2 ;9,089,496…2017 2 January 2019 1:17-cv-01793 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Neos Therapeutics v. Teva Pharmaceuticals Patent Litigation: Case No. 1:17-cv-01793

Last updated: August 8, 2026

Neos Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., Case No. 1:17-cv-01793, was a Hatch-Waxman patent infringement action in the U.S. District Court for the District of Delaware. Neos sued after Teva filed an abbreviated new drug application seeking approval for a generic version of a Neos amphetamine extended-release orally disintegrating tablet. The dispute concerned Neos’s drug-delivery technology and Orange Book-listed patents covering extended-release orally disintegrating formulations.

The case ended without a reported trial judgment or Federal Circuit merits decision. The public docket reflects a negotiated resolution and dismissal. The principal commercial issue was whether Teva could enter the market before expiration of Neos’s formulation patents.

What drug and ANDA were involved in Neos v. Teva?

The litigation involved a proposed generic version of Neos’s amphetamine extended-release orally disintegrating tablet product, commercially marketed as Adzenys XR-ODT.

Adzenys XR-ODT contains amphetamine and is approved for the treatment of attention-deficit/hyperactivity disorder. It is an orally disintegrating tablet designed to provide extended release without requiring the patient to swallow a conventional tablet. The product uses Neos’s modified-release oral dosage-form technology.

The case was based on Teva’s filing of an ANDA with a Paragraph IV certification. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the ANDA product. Filing the certification created the statutory basis for Neos’s infringement suit under the Hatch-Waxman Act. [1]

Case identification

Item	Information
Case	Neos Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01793
Action type	Hatch-Waxman patent infringement
Plaintiff	Neos Therapeutics, Inc.
Defendant	Teva Pharmaceuticals USA, Inc.
Technology	Amphetamine extended-release orally disintegrating tablet
Regulatory filing	Teva ANDA with Paragraph IV certification
Product associated with patent estate	Adzenys XR-ODT
Disposition	Resolved and dismissed without a reported merits judgment

What patents protected Adzenys XR-ODT in the litigation?

Neos’s relevant patent estate centered on patents covering pharmaceutical compositions and extended-release orally disintegrating dosage forms. The principal patents associated with Adzenys XR-ODT included the following:

Patent	General subject matter	Relevance to Neos product estate
U.S. Patent No. 8,877,778	Amphetamine pharmaceutical compositions and extended-release delivery	Core composition and formulation protection
U.S. Patent No. 9,192,662	Extended-release orally disintegrating tablets	Dosage-form and release-profile protection
U.S. Patent No. 9,763,856	Later-generation orally disintegrating and controlled-release formulation claims	Additional formulation and continuation protection

The precise claims asserted against Teva must be distinguished from the broader Orange Book listing. Patent complaints commonly assert selected claims from listed patents, while the Orange Book may contain multiple patents covering different aspects of a product.

The estate was commercially important because it combined several layers of protection:

1. The active pharmaceutical ingredient and pharmaceutical composition.
2. The orally disintegrating tablet platform.
3. The extended-release profile.
4. Excipients, matrix components, and manufacturing characteristics.
5. Product-specific use or dosage limitations.

A generic applicant could therefore face infringement exposure even if it did not copy the branded product’s trade dress, inactive ingredients, or manufacturing process exactly.

When did the Neos patents expire?

The principal patents had expiration dates extending into the late 2020s and early 2030s, depending on the patent, applicable patent-term adjustment, and the specific Orange Book listing.

Patent	Estimated statutory term position	Commercial implication
U.S. 8,877,778	Late 2020s	Earlier-expiring core formulation protection
U.S. 9,192,662	Around 2030-2031	Extended protection for the orally disintegrating platform
U.S. 9,763,856	Around 2030-2031	Later continuation protection

The controlling dates are the FDA Orange Book entries and the USPTO patent-term records, not an unadjusted 20-year estimate. Patent-term adjustment can move the effective expiration date. The Orange Book also distinguishes patents by product and patent use code, which affects the scope of a generic applicant’s certification obligations. [2, 3]

The practical consequence was that Teva’s approval and launch timing depended on the earliest enforceable barrier that covered its ANDA product. If Teva prevailed on all asserted claims, it could potentially obtain approval before the latest patent expiration. If Neos prevailed, FDA approval would generally be delayed until the applicable 30-month stay and patent-barrier period ended, unless the parties settled on an earlier licensed entry date.

What was the Paragraph IV challenge in Neos v. Teva?

Teva’s Paragraph IV filing likely challenged the validity, enforceability, or infringement of Neos’s listed patents. The standard defenses in this type of case include:

• Anticipation under 35 U.S.C. § 102.
• Obviousness under 35 U.S.C. § 103.
• Lack of written description or enablement under 35 U.S.C. § 112.
• Noninfringement based on differences between the ANDA formulation and the asserted claims.
• Improper patent listing or lack of statutory coverage.
• Patent-term or regulatory defenses.

For orally disintegrating extended-release products, the technical dispute usually turns on whether the ANDA formulation satisfies limitations involving dissolution, particle size, release-control agents, dosage-form structure, and pharmacokinetic performance.

A formulation claim can be difficult to design around when the claim is defined by measurable product characteristics rather than a specific manufacturing recipe. Conversely, a generic defendant may avoid infringement if its formulation produces a different release profile or uses a materially different release-control mechanism.

How strong was Neos’s patent estate?

Neos’s patent position was stronger than a single-patent estate because it covered several related technical features. Its commercial strength came from claim layering rather than from the active ingredient alone.

Composition claims

Composition claims can capture the product’s combination of amphetamine and release-controlling excipients. Their strength depends on how narrowly the claims define the ingredients and concentrations. Narrow claims may be easier to design around but can provide stronger protection against substantially similar formulations.

Dosage-form claims

Claims directed to orally disintegrating tablets can cover tablet disintegration, drug release, taste masking, particle distribution, and excipient selection. These claims are important because a generic sponsor must reproduce the product’s administration route and release characteristics while satisfying FDA bioequivalence requirements.

Performance-based claims

Claims based on dissolution or pharmacokinetic parameters can create a meaningful barrier if the ANDA product necessarily meets the claimed profile. Their enforceability depends on claim construction, testing protocols, and whether the generic product’s approved labeling or manufacturing controls establish infringement.

Continuation protection

The presence of related patents and continuation filings can extend practical patent coverage after an earlier patent expires. Continuation patents do not extend the term of the original disclosure beyond the applicable statutory limit, but they can produce different claims directed to separate technical features.

The weakness was that formulation patents are often vulnerable to obviousness attacks based on combinations of known extended-release and orally disintegrating technologies. Teva also had an incentive to argue noninfringement by changing excipient ratios, release-control materials, or manufacturing parameters.

What was the outcome of the litigation?

The case did not produce a publicly reported trial decision invalidating or upholding the asserted patents. The docket reflects a negotiated resolution followed by dismissal rather than a merits judgment. [4]

The public record does not establish a detailed public settlement term sheet. As a result, the following commercial terms cannot be treated as confirmed from the litigation docket:

• Teva’s authorized or licensed launch date.
• Whether Teva received a license to launch before all patent expirations.
• Whether Teva agreed to supply restrictions.
• Whether Neos received a monetary payment.
• Whether the agreement included a no-challenge provision.
• Whether the settlement covered other Neos products or related affiliates.

The dismissal closed the specific Teva action. It did not, by itself, invalidate Neos’s patents, remove the patents from the Orange Book, or resolve challenges by other generic applicants.

Did the case affect FDA approval or Orange Book status?

The litigation triggered the Hatch-Waxman 30-month stay associated with Neos’s receipt of a Paragraph IV notice. The stay generally prevents FDA approval of the ANDA for the statutory period unless the litigation is resolved earlier or a court orders otherwise. [1]

The suit did not convert Adzenys XR-ODT into a biologic or create biosimilar-style regulatory exclusivity. Amphetamine is a small-molecule active ingredient, and Teva’s application proceeded through the ANDA pathway rather than the abbreviated pathway under the Public Health Service Act.

Orange Book consequences included:

• Continued listing of eligible Neos patents unless FDA later determined that a listing was improper.
• Continued relevance of the listed patents to subsequent ANDA certifications.
• Potential use of different patent certifications for different strengths, dosage forms, or labeling indications.
• Possible carve-out issues if a patent covered only a method of use.

Orange Book listing does not determine patent validity. It identifies patents that the NDA holder asserts cover the approved drug, its formulation, or an approved method of use. [2]

Were method-of-use patents involved?

The commercial dispute was principally formulation-driven. Adzenys XR-ODT’s patent estate was associated primarily with the extended-release orally disintegrating dosage form and its composition.

Method-of-use patents could still affect a generic launch if a listed patent covered an indication or dosing regimen. In that situation, Teva could attempt a section viii labeling carve-out that omitted the patented use. A carve-out is less useful when the patented method overlaps with the product’s central FDA-approved indication or when the formulation itself is claimed.

The public case record does not establish that the dispute turned on a standalone method-of-use patent. The stronger analytical focus is therefore on composition, dosage-form, and release-profile claims.

What generic-entry risks existed for Neos?

Neos faced several generic-entry risks even with a multi-patent estate.

Risk of noninfringing design-around

Teva could modify the formulation while preserving bioequivalence. A successful design-around would reduce the value of composition or excipient claims that depended on narrow concentration ranges.

Risk of invalidity

Extended-release and orally disintegrating technologies draw on well-developed prior art. Obviousness risk was therefore material, particularly for claims combining familiar excipients, release mechanisms, and tablet properties.

Risk from multiple ANDA filers

A settlement with Teva would not necessarily prevent other generic manufacturers from challenging the same patents. A first filer could also create a market entry benchmark that reduced the branded product’s negotiating leverage with later applicants.

Risk from patent-term compression

A settlement with a launch date close to patent expiration may provide limited protection. The value of the estate depended on the difference between the negotiated entry date and the effective expiration of the last enforceable patent.

How did Neos’s estate compare with competing ADHD products?

Neos’s patent strategy differed from products based on conventional swallowed capsules or tablets.

Product type	Primary protection	Generic or biosimilar pathway	Main barrier
Adzenys XR-ODT	Orally disintegrating extended-release formulation	ANDA	Formulation patents and Paragraph IV litigation
Conventional amphetamine tablet	Active ingredient and formulation	ANDA	Earlier generic competition
Extended-release capsule	Release mechanism and multiparticulate technology	ANDA	Composition, bead, and release-profile patents
Methylphenidate ODT	Orally disintegrating extended-release formulation	ANDA	Similar formulation and dissolution disputes
Biologic ADHD therapy	Not generally applicable	Biosimilar pathway	No meaningful biosimilar issue for amphetamine

Neos’s delivery technology gave it a differentiated product profile, but it also concentrated patent risk in formulation claims. A generic sponsor did not need to reproduce the branded manufacturing process if it could achieve the required clinical and pharmaceutical performance through another formulation.

What licensing and settlement issues mattered commercially?

The principal licensing issue was whether Teva received an authorized entry right. Hatch-Waxman settlements often establish a future launch date, but the date and other terms may remain confidential.

From a business perspective, the material settlement variables were:

• The licensed entry date.
• Whether entry was contingent on patent litigation involving another generic.
• Whether Teva could launch an authorized generic.
• Whether the agreement covered all strengths and dosage forms.
• Whether Neos retained the right to sue over later Teva formulation changes.
• Whether the settlement included supply, co-promotion, or royalty provisions.

Because the public docket did not report a merits decision, the case should be treated as a settlement-based resolution rather than as judicial confirmation of patent validity.

What is the current litigation and competitive status?

The specific action, Case No. 1:17-cv-01793, is closed. There is no reported ongoing trial, injunction, or appellate proceeding in that case.

The broader competitive assessment remains separate from the docket outcome:

• Neos’s patents may still affect later ANDA applicants.
• A dismissal does not remove Orange Book patents.
• The settlement may permit Teva entry on confidential or future terms.
• Generic competition depends on Teva’s commercial launch, FDA approval, and any remaining patent or regulatory barriers.
• No biosimilar pathway applies because the product is a small-molecule amphetamine drug.

Key Takeaways

• Neos sued Teva in Delaware after a Paragraph IV ANDA challenge involving an amphetamine extended-release orally disintegrating tablet.
• The dispute was tied to Adzenys XR-ODT and Neos’s formulation and drug-delivery patent estate.
• The principal patents included U.S. Patent Nos. 8,877,778, 9,192,662, and 9,763,856.
• The case ended through negotiated resolution and dismissal, without a reported merits judgment.
• The public docket does not establish the settlement’s launch date, payment terms, or license scope.
• The litigation involved an ANDA, not a biosimilar application.
• Neos’s strongest protection came from layered formulation, dosage-form, and release-profile claims.
• The principal generic risks were obviousness, noninfringing design-around, and additional Paragraph IV challenges.

FAQs About Neos Therapeutics v. Teva

Could Teva launch a generic before the last Neos patent expired?

Only if Teva obtained an agreed license, prevailed on the asserted patents, secured a court-ordered remedy, or relied on a product configuration not covered by enforceable claims.

Did the Neos-Teva settlement invalidate the patents?

No. A dismissal pursuant to settlement does not invalidate or judicially uphold the patents.

Was Adzenys XR-ODT protected by new chemical entity exclusivity?

The central dispute was patent-based. NCE exclusivity, if applicable to the NDA’s regulatory history, would be separate from the Paragraph IV patent litigation and does not determine patent validity.

Could another generic manufacturer challenge the same Neos patents?

Yes. A settlement with Teva does not automatically bind unrelated ANDA applicants or eliminate the statutory right to file a Paragraph IV certification.

Are biosimilars a competitive threat to Adzenys XR-ODT?

No. Adzenys XR-ODT contains a small-molecule amphetamine active ingredient and competes through the ANDA generic pathway rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process and Paragraph IV certifications. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

3. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. USPTO.

4. U.S. District Court for the District of Delaware. (2017-2019). Neos Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:17-cv-01793, public docket.